ZenovaMD Revive

(

80

review)

Topical – Dutasteride, Minoxidil & Tretinoin

Advanced Daily Topical – designed for men and women seeking maximum regrowth potential

‍

Core Benefits – reduces shedding, blocks DHT more effectively and supports stronger thicker hair
Ingredient Breakdown:
- Dutasteride (0.1%) – dual 5-alpha reductase inhibitor that blocks more DHT than finasteride
- Minoxidil (5%) – stimulates follicles and strengthens hair
- Tretinoin (0.025%) – improves absorption and scalp health

‍

Doctor-Formulated & Supported – safe, physician monitored with 24/7/365 support

Get Started Today

Plans, Packages & Pricing

1-month supply + full support

3-month supply + bundled savings

6 month supply + best value

All plans include unlimited telehealth and free, discreet shipping.

The assessment available on the ZenovaMD website does not create a doctor–patient relationship. Clinical services are provided by OpenLoop Health and other networks of U.S.-licensed clinicians who determine eligibility for GLP-1 treatment based on medical history and assessment responses. Providers retain full discretion to prescribe or decline compounded GLP-1 medications. Compounded medications offered through ZenovaMD are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. Results may vary and depend on individual adherence, provider guidance, and lifestyle changes. ZenovaMD does not manufacture compounded medications, and product appearance may differ from website images. ZenovaMD partners with certified U.S. pharmacies to ensure high standards of safety and quality. Medication costs are included in the ZenovaMD program. Zepbound® is FDA-approved for chronic weight management; Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight management. All trademarks are the property of their respective owners. Unless otherwise noted, results reflect ZenovaMD patient experiences rather than public clinical studies.